Skip to main content
Clinical Trials/EUCTR2017-002175-25-DE
EUCTR2017-002175-25-DEActive, not recruitingPhase 1

Effects on blood pressure and central sympathetic nerve traffic by SGLT2-inhibition with empagliflozin compared to hydrochlorothiazide in patients with type 2 diabetes mellitus

Profil Institut für Stoffwechselforschung GmbH0 sites60 target enrollmentStarted: July 26, 2017Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
60

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • women and men = 50 and = 80 years of age
  • type 2 diabetes mellitus for = 2 years
  • only metformin monotherapy is allowed; metformin dose must have been stable for = 12 weeks
  • stable or no antihypertensive treatment
  • HbA1c = 6.5% and = 10.0%
  • body mass index > 25 kg/m2 and < 40 kg/m²
  • systolic blood pressure between 110 mm Hg and 160 mm Hg and diastolic blood pressure >= 60 mmHg
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 30
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

Exclusion Criteria

  • heart failure NYHA II – IV
  • eGFR < 60 ml/min/1.73 m²
  • patients with prior severe cardiovascular disease (MI, stroke, vascular intervention) within the last 12 months
  • patients with a history of ketoacidosis
  • patients with frequent genital and lower urinary tract infections
  • acute and chronic liver disease or screening alanine transaminase or aspartate transaminase > 3 x ULN
  • signs of a clinically significant infection as judged by the investigator
  • clinical signs of volume depletion
  • potassium < 3.5 mmol/l
  • concomitant drug therapy not allowed in the study

Investigators

Similar Trials